C3 and primary membranoproliferative glomerulonephritis: Taken together, these improvements suggest that by directly inhibiting C3 and C3b in all 3 complement pathways, pegcetacoplan may target the underlying mechanism of disease in both C3G and primary IC-MPGN and make the treatment goal of prolonged renal survival a possibility.